Welcome to our dedicated page for Tectonic Therapeutic SEC filings (Ticker: TECX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tectonic Therapeutic, Inc. (NASDAQ: TECX) SEC filings page brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tectonic is a clinical-stage biotechnology company focused on GPCR-targeted biologic medicines, and its filings provide structured insight into financial results, clinical development updates and corporate events.
Investors can use this page to access Form 10‑Q and Form 10‑K reports, which contain detailed discussions of Tectonic’s research and development activities, risk factors, and financial statements. For a company advancing programs such as TX45 in Group 2 pulmonary hypertension and PH‑ILD, and TX2100 for Hereditary Hemorrhagic Telangiectasia, these periodic reports explain how clinical trial progress and pipeline strategy relate to operating expenses and liquidity.
The page also surfaces Form 8‑K current reports, where Tectonic discloses material events such as quarterly financial results, positive topline clinical data, updated corporate presentations, and other significant announcements. These filings often reference attached press releases and slide decks that elaborate on trial designs, endpoints, and topline outcomes.
In addition, users can review Section 16 filings such as Form 4, which report changes in beneficial ownership by directors, officers, and other insiders, as well as proxy materials that discuss governance and executive compensation. Stock Titan’s platform layers AI-powered summaries on top of these documents to highlight key points, explain technical language, and help readers quickly understand the implications of lengthy filings without replacing the underlying source documents.
Together, the TECX SEC filings and AI summaries give a structured view of how Tectonic communicates its financial condition, clinical-stage risks, and strategic focus on GPCR-targeted biologics to regulators and investors.
Tectonic Therapeutic, Inc. reported an insider stock option exercise by Chief Business Officer Marc Schwabish. On February 10, 2026, he exercised an employee stock option for 4,500 shares of common stock at an exercise price of $2.38 per share.
Following this transaction, Schwabish directly owned 25,814 shares of common stock and held 82,014 employee stock options. The option originally vested beginning March 15, 2022, with remaining shares vesting in equal monthly installments over 36 months, subject to continued service.
Tectonic Therapeutic, Inc. Chief Financial Officer Daniel Lochner reported an open-market purchase of 6,000 shares of the company’s common stock on February 10, 2026, at a weighted average price of $21.61 per share. Following this transaction, he directly beneficially owns 32,044 common shares.
The purchase price reflects multiple trades executed in a range from $21.24 to $21.82 per share, as disclosed in the footnote. This filing documents increased personal share ownership by a senior executive through market purchases.
Tectonic Therapeutic, Inc. insider activity: Chief Business Officer Marc Schwabish reported a routine tax-related share withholding. On February 4, 2026, 1,619 shares of common stock were withheld by the company at $23.22 per share to cover his tax obligations from vesting restricted stock units granted on February 4, 2025. After this transaction, Schwabish directly beneficially owned 21,314 shares of Tectonic Therapeutic common stock.
Tectonic Therapeutic, Inc. reported that Chief Medical Officer Marcella K. Ruddy had 2,064 shares of common stock withheld on February 4, 2026. The company withheld these shares to cover her tax obligations related to the vesting and settlement of restricted stock units granted on February 4, 2025. After this tax withholding, she directly beneficially owned 53,247 common shares of Tectonic Therapeutic.
Tectonic Therapeutic, Inc. reported a routine share withholding related to its Chief Executive Officer, Alise Reicin. On February 4, 2026, the company withheld 4,104 shares of common stock at $23.22 per share to cover her tax obligations from vesting restricted stock units granted on February 4, 2025.
Following this transaction, Reicin beneficially owned 235,047 shares directly. An additional 124,530 shares were held indirectly through the Reicin-Boiarsky Family Trust, where she may share voting and dispositive power but disclaims full beneficial ownership beyond her economic interest.
Tectonic Therapeutic, Inc. insider Peter McNamara, Chief Scientific Officer, reported a routine share withholding related to equity compensation. On February 4, 2026, the issuer withheld 1,748 shares of common stock at $23.22 per share to cover his tax obligations on vested restricted stock units, leaving him with 39,131 directly held shares.
Tectonic Therapeutic, Inc.'s Chief Financial Officer, Daniel Lochner, reported a routine share withholding transaction. On February 4, 2026, the issuer withheld 2,077 shares of common stock at $23.22 per share to cover the officer’s tax obligations from vesting restricted stock units granted on February 4, 2025.
After this tax-related withholding, the reporting person directly beneficially owned 26,044 shares of common stock. This reflects administrative equity compensation activity rather than an open-market purchase or sale.
Aberdeen Group plc and its affiliate abrdn Inc report beneficial ownership of 1,141,824 shares of Tectonic Therapeutic, Inc. common stock, representing 6.10% of the class as of 12/31/2025.
The firms have shared voting and dispositive power over all of these shares and no sole voting or dispositive authority. They state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Tectonic Therapeutic.
Tectonic Therapeutic (TECX) reported Q3 2025 results, highlighting continued R&D investment and a solid balance sheet. Net loss was $19.0 million (basic and diluted EPS $(1.02)) on operating expenses of $21.9 million, including R&D $16.9 million and G&A $5.0 million. Interest income was $2.9 million.
Cash and cash equivalents were $268.4 million as of September 30, 2025, and stockholders’ equity was $267.5 million. The company closed a February 2025 private placement for net proceeds of $173.1 million. Management believes current cash will fund planned operations for at least 12 months from the financial statements’ issuance date.
Pipeline updates: TX45 advanced with positive Phase 1b hemodynamic data in PH-HFpEF and PH-HFrEF, and the 24‑week, placebo‑controlled APEX Phase 2 trial (SC dosing) is ongoing with topline results expected in 2026. TX2100 completed IND‑enabling NHP GLP tox in 2025, with a Phase 1 in healthy volunteers planned for early 2026.
Tectonic Therapeutic, Inc. filed a current report to note that it announced financial results for the quarter ended September 30, 2025 and shared a general business update on November 6, 2025. These details are contained in a press release furnished as an exhibit to the report.